Ozempic’s expanded approval in the U.S. could transform how doctors treat patients with the condition, which involves a ...

The U.S. FDA has approved Novo Nordisk's Ozempic for reducing the risk of kidney failure and disease progression, as well as ...

Novo Nordisk agreed to cap insulin prices to settle a lawsuit in which Minnesota's attorney general accused the three largest ...

Ozempic, or semaglutide, can now be used to reduce the risk of worsening kidney disease or kidney failure in adults with type ...

Minnesota Attorney General Keith Ellison says his office has settled with the last of the three largest insulin manufacturers ...

Ozempic belongs to a class of drugs known as GLP-1 receptor agonists and has the same active ingredient as the company's ...

This story incorporates reporting fromdevdiscourse, WJON and KIMT.Novo Nordisk has settled a lawsuit with Minnesota, agreeing ...

Here are some of the major companies whose stocks moved on the week’s news.

Novo Nordisk's U.S.-listed shares are surging 9% Friday morning after the Danish drugmaker reported early stage results for ...

Novo Nordisk shares jumped on Friday as the Danish drugmaker said an experimental drug was able to reduce weight by as much ...

Allurion catapulted nearly 200% early Friday after the company said it plans to test its weight-loss technology with an ...